Capsaicin dermal patch - NeurogesX

Drug Profile

Capsaicin dermal patch - NeurogesX

Alternative Names: 8% capsaicin patch - NeurogesX; Capsaicin; NGX-4010; Qutenza; Transacin; Transdolor™ Pain Treatment System

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeurogesX
  • Developer Astellas Pharma Europe Ltd; NeurogesX
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Postherpetic neuralgia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Neuropathic pain; Postherpetic neuralgia
  • Registered Diabetic neuropathies
  • No development reported Postoperative pain

Most Recent Events

  • 12 Dec 2016 Astellas enters into a definitive agreement with Grünenthal for transfer of exclusive rights to Qutenza in Europe, Middle East and Africa
  • 29 Apr 2016 Biomarkers information updated
  • 19 Nov 2015 Safety and efficacy data from the head-to-head ELEVATE trial for peripheral Neuropathic pain released by Astellas
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top